Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (June 2021)
46 slides from Corbus Pharmaceuticals's investor presentation, Jun 1, 2021
Slide 1: Connecting Innovation to Purpose
— PHARMACEUTICALS Sed Connecting Innovation to Purpose May 2021 NASDAQ: CRBP - CorbusPharma.com - @CorbusPharma
Slide 2: Forward-Looking Statements
ee FORWARD-LOOKING STATEMENTS This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the
Slide 3: Expanding Our Therapeutic Focus
Expanding Our Therapeutic Focus /-——_—_____ CONTINUED FOCUS ———} INFLAMMATION \ Expertise across all phases of _ drug development {© \ Track record of executing | complex global studies on / time and on budget J Funded through Q1 2024
Slide 4: A Diverse Pipeline with Multiple Shots on Goal
A Diverse Pipeline with Multiple Shots on Goal } Compound | Therapeutic Areas / Indications | Preclinical Phase 1 Phase 2 Phase 3 Dermatomyositis Lenabasum riplis CB1 Inverse Agonists Metabolism CB2 Agonists Solid Tumors Anti-avB8 mAb Solid Tumors Anti-avB6/avB8 mAb Fibrosis CB1 = cannabinoid recept
Slide 5: Program 1: Targeting the Endocannabinoid System
PROGRAM 1: TARGETING THE ENDOCANNABINOID SYSTEM
Slide 6: Endocannabinoid System
Endocannabinoid System 2 GPCRs: CB1 and CB2 2 endogenous agonists: anandamide & 2-AG Metabolic enzymes FAAH and MAGL Haspula, et al. Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases,
Slide 7: Lenabasum: A Late-Stage CB2 Agonist for Autoimmune Diseases
LENABASUM: A LATE-STAGE CB2 AGONIST FOR AUTOIMMUNE DISEASES
Slide 8: Lenabasum: CB2 Agonist In Late-Stage Development
Lenabasum: CB2 Agonist In Late-Stage Development PURPOSE Inflammatory and fibrotic diseases INNOVATION * First-in-class © Targets activated immune cells * Non-immunosuppressive * Add-on to current therapies MOA * Activates resolution of inflammation » Reduces levels of inflammatory mediators Inhibit
Slide 9: Key Lenabasum Phase and Studies
Key Lenabasum Phase 2 and 3 Studies Target (Program) Trial Size (n) Dermatomyositis 3 176 + Topline data expected Q2 2021 Cystic Fibrosis 2b 425 + Primary efficacy endpoint (pulmonary exacerbation rate) was not met + Acceptable safety profile + Not planning additional studies in CF SLE 2 100 + Ongoi
Slide 10: What is Dermatomyositis?
What is Dermatomyositis? yr - DERMATOMYOSITIS: Arare and life-threatening autoimmune sy 7 j disease characterized by skin and muscle = , * be inflammation. — Images provided by Myositis Support and Understanding and The Myositis Association; % ‘Health Advances, LLC Analysis | “Schiopu et al, 2012 Af
Slide 11: Phase DM Study - Improvement in Skin Activity and Biomarkers
Phase 2 DM Study - Improvement in Skin Activity and Biomarkers ACDASI Activity Score, Mean + SE -15 -20 25 Placebo BPC =®LenabasumDBPC —=®=Lenabasum OLE 02468 1216 04 12% 2 3% 44 82 GO 68 76 SF 92 10 10 MIG 126 132 140 48 156 Weeks Week 0 DBPC CDASI activity score mean (SD) = 33.3 (9.74) for lenabas
Slide 12: Dermatomyositis: Topline Phase Study Results Expected 2021
Dermatomyositis: Topline Phase 3 Study Results Expected 02 2021 Trial in Adults with Active Classic or Amyopathic Dermatomyositis PRIMARY ENDPOINT IN U.S. & EU: e ACR &EULAR 2016 Total Improvement Score (TIS) in Adult Dermatomyositis and Polymyositis at Week 28, lenabasum BID vs. placebo (n = 176) K
Slide 13: Systemic Lupus Erythematosus (SLE): Topline Phase Study Results Expected
Systemic Lupus Erythematosus (SLE): Topline Phase 2 Study Results Expected 2H 2027 % PRIMARY ENDPOINT: e Mean 7-day average maximum daily pain numerical rating score (NRS) at 12 weeks, n= 101 STUDY FUNDED AND MANAGED BY THE AUTOIMMUNITY CENTERS OF EXCELLENCE AT THE KEY SECONDARY ENDPOINTS: NATIONAL
Slide 14: 2nd Generation CB1 Inverse Agonists for Metabolic and Fibrotic Diseases
2ND GENERATION CBT INVERSE AGONISTS FOR METABOLIC AND FIBROTIC DISEASES
Slide 15: Slide 15
Slide 16: Obesity is a Growing Global Health Crisis
Obesity is a Growing Health t
Slide 17: CB1 Activation Contributes To Diabesity
CB1 Activation Contributes To “Diabesity” CB1 ACTIVATION INCREASES: + Appetite + Food intake + Fat production and storage + Insulin resistance + Inflammation + Fibrosis CB1 ACTIVATION DECREASES: + Insulin secretion + Fat oxidation + Energy expenditure DDeeba, et al. Targeting the endocannabinoid sys
Slide 18: CB1 is a Validated Target in Metabolic Diseases
CBT1is a Validated Target in Metabolic Diseases | SEVERAL FIRST GENERATION CB1 INVERSE AGONISTS ADVANCED TO LATE-STAGE CLINICAL DEVELOPMENT bn | ! SANOFI \% ore | _ SECOND GENERATION OF Rimonabant _ CBIINVERSE AGONISTS eS P, zer | ¢ Approved in EU and launched in 2006 for treatment AIM TO MAINTAIN o
Slide 19: CB1 Inverse Agonist Program
CB1 Inverse Agonist Program PURPOSE * Obesity, diabetes/diabetic nephropathy, NASH INNOVATION Second generation small molecule with Pancreas limited brain levels to increase safety « Potential to augment effects of GLP-1R agonists in diabetes and obesity * Potential to preserve renal function MOA e
Slide 20: DIO Model: CRB-556 Induces Weight Loss in Obese Mice
DIO Model: CRB-556 Induces Weight Loss in Obese Mice * CBlinverse agonist CRB-556 induced dose-dependent weight loss in mice with diet-induced obesity 7 lb CRB-556 5 mg/kg BID + Effect similar to rimonabant ~ -@ Rimonabant 10 mg/kg QD 4% CRB-556 10 mg/kg BID High fat diet Mice received a high-fat di
Slide 21: DIO Model: CRB-556 Improves Glucose Tolerance and Insulin Sensitivity
DIO Model: CRB-556 Improves Glucose Tolerance and Insulin Sensitivity in Obese Mice Vehicle BID -© Rimonabant 10 mg/kg QD -® CRB-556 5 mg/kg BID -@ CRB-556 10 mgikg BID 3504 oGTT ee iT CRB-556 improved glucose tolerance and insulin sensitivity in mice with diet-induced obesity, similar to rimonabant
Slide 22: CRB-4001 Augments Weight Loss Provided by Semaglutide in Obese Mice
CRB-4001 Augments Weight Loss Provided by Semaglutide in Obese Mice », CB1inverse agonist CRB-4001 augmented semaglutide-induced weight loss in obese mice and insulin sensitization (improved ~® Semaglutide + CRB-4001 basal glucose levels and glucose disappearance rate) -@ Vehicle ~® Semaglutide -@®
Slide 23: CRB-4001 in Diabetic Nephropathy Model
#P < 0.05 relative to the corresponding streptozotocin (STZ) group treated with vehicle (Veh) C57BI/6 mice with STZ-induced diabetic nephropathy were treated for 16 weeks with 3 mg/kg CRB-4001. Compared to the STZ group treated with vehicle. CRB-4001 INCREASED: CRB-4001 DECREASED: + Preservation of
Slide 24: Select Corbus CB1 Inverse Agonists Have Low Brain Levels
Select Corbus CB1 Inverse Agonists Have Low Brain Levels and Receptor Occupancy With Re €B1 Receptor (hn AUC p24 Occupancy in Brain, Compound Brain: Plasma Brain: Plasma Chronic Dosing, Comment (Ratio, Range) (Ratio, Range) 10-20 mg/kg i . Upper limit of Rimonabant (Sanofi) 0.90->1 = quantita Single
Slide 25: New Drug Class: Cannabinoid Receptor Agonists for Solid Tumors
NEW DRUG CLASS: CANNABINOID RECEPTOR AGONISTS FOR SOLID TUMORS
Slide 26: CB2 Agonist Immuno-oncology Program
CB2 Agonist Immuno-oncology Program PURPOSE Solid tumors in combination with standard treatments including checkpoint inhibitors INNOVATION © First-in-class * Affects both tumor cells and immune system * Potential to augment effects of CPIs MOA e Inhibits cell cycle progression Inhibits cell prolife
Slide 27: Corbus CB2 Agonists Reduce Cancer Cell Viability by Promoting Apoptosis
Corbus CB2 Agonists Reduce Cancer Cell Viability by Promoting Apoptosis ¥ Inhibition of cancer cell viability, IC50 (uM) Compound CRB-199* CRB-378* 8.0 "Curent candidates under evalation for ‘potential nical development 50 20 Fold Induction (vs. DMSO) Fold Induction (vs. DMSO) 10 | 00 cRB-199 cRB-37
Slide 28: CRB-378 Has Single Agent Activity in Her2+ Breast Cancer Xenograft Model
CRB-378 Has Single Agent Activity in HCC1954 Her2+ Breast Cancer Xenograft Model x CRB- 378 REDUCES TUMOR VOLUME CRB- 378 IS CONCENTRATED IN THE TUMOR * Vehicle Al CRB-378 5 mg/kg (tumor) 1400 —® CRB-378, 5 mg/kg BID —t- CRB-378 10 mg/kg (tumor) £ 1200 -- CRB-378, 10 mg/kg BID 1000 -@- CRB-378 5mg/k
Slide 29: Program 2: Targeting TGFB Activating Integrins
PROGRAM 2: TARGETING TGFB ACTIVATING INTEGRINS
Slide 30: Immune Evasion is Mediated by TGF B in Late-Stage Tumors
Immune Evasion is Mediated by TGF B in Late-Stage Tumors Pro-inflammation 1-17, @) Pro-Inflammation dig Cancer Cells TME Human ssi © Pw \ ¥ £150 —— niaseningeee” a TSE : ws I & OP, Macrophage ut) 5310 . —_ 06 ser oO + i > 60 am, ‘J SY ‘Sate 3) 5 0 Timonpronetng o<5 p8 TPS oI e Mast Cells (G29) Peosr
Slide 31: Lower Survival in Patients with High TGF Tumor Gene Signature
Lower Survival in Patients with High TGF Tumor Gene Signature y IN CONCORDANCE WITH LOW DEATH RISK ii a HIGH DEATH RISK 8 oor Overall survival, % N= 8,461 cancers, multiple cell types 04 06 0.8 er Nd o TGFB predominance iJ gene signature St + + +r + + is) 5 10 15 20 25 Time, years “ Strong concordan
Slide 32: avB8 on Tumor Cells Activates TGF
avB8 on Tumor Cells Activates TGF DIFFUSIBLE ACTIVE TGFB NON-DIFFUSIBLE ACTIVE TGFB 1 NVA a Litnart etal Stucturalbasis of latent T6F-61 ‘resentation and activation by GARPon human reguatory Tels, Science 2018:3624. Non-diffusible TGFB may be most relevant form of active TGFB in cancer
Slide 33: Drug Development of Inhibitors of TGF B-Activating Integrins
Drug Development of Inhibitors of TGF B-Activating Integrins ONCOLOGY PHASE (asoseo worn, (osexasen moan) Phase 1 @Pfizer Solid tumors: cre Prd Preclinical ops @ Phase 2 aves @ PLIANT | IPF aPSC. MORPHICZS Preclinical vps @ Preclinical api @ as wi ‘MONOCLONAL ANTIBODY @ sunocnz VENN Preclinical aves
Slide 34: CRB-601: Anti-avB8 mAb
CRB-601: Anti-avB8 mA PURPOSE Treatment of solid tumors, in combination with standard treatments including checkpoint inhibitors a pro- L-TGF-B domain INNOVATION Anti-avB8 mAb from Nishimura lab (UCSF) * Genealogy: mC6D4 > hC6D4 > CRB-601 * Potential to augment effects of CPIs av B- MOA propeller «
Slide 35: C6D4 Inhibits Activation of Both Diffusible and Non-Diffusible TGFB
C6D4 Inhibits Activation of Both Diffusible and Non-Diffusible TGFB Inhibition of Activation of: Non-Diffusible TGFB Diffusible T6FB z & = > Anti-B8 (CD64) = > Anti-ps (C064) 2 © Anti-TGF-B gy © Anti-TGF-p en ~ TOF-BR2-fc g © TOF-BR2-fe g = Anti-TGF-BR2 8 © Anti-TGF-BR2 a “> Anti-GARP/L-TGF-B o “> A
Slide 36: Parental C6D4 Anti-avB8 mAb Augments Activity of Anti-PD-1 mAb
Parental C6D4 Anti-avB8 mAb Augments Activity of Anti-PD-1 mAb MC38 Syngeneic Mouse Colon Cancer Model © 1000 Sid £ 100 5 800 3 80 te 3 eo 5 oo ° * iF “Isotype control Abs i fa) 3 40 © cans > ix —% anti-PD-1mAb 5 200 20 = C6D4 + anti-PD-1 mAbs 5 6 . - 1 0 0 gtt thio tt tis 0 2 4 6 8 101214 16 18 20
Slide 37: Blocking Both TGF and PD-1 Augments T Cell Infiltration in Tumors
Blocking Both TGF and PD-1 Augments T Cell Infiltration in Tumors + Majority of infiltrating cells are CD8+ T cells * Consistent with lessening immunosuppression Tumour periphery Tumour centre + CRB-601 + anti-PD-1 mAb have the potential to provide superior relief of inmunosuppression \Mariathsasan
Slide 38: CRB-602: Anti-avB6/8 mAb for Fibrosis and Cancer
CRB-602: Anti-civ 36/8 mAb for Fibrosis and Cancer INCREASED EXPRESSION OF cov 36 IN FIBROTIC AREAS IN LUNG OF © Tish fein rence ESET IDIOPATHIC PULMONARY FIBROSIS (IPF) SUBJECTS + avf6 integrin also activates TGFB 1PETimage ¢ 2% PET scan + av6 is expressed in high levels on tumors of epithelial ori
Slide 39: Expected Clinical Milestones 2021-2022
Expected Clinical Milestones 2021-2022 y PROGRAM PHASES DATA PHASE 2 DATA PHASE 1 PHASE 1 PHASE 1 PHASE 1
Slide 40: Financial Profile: CRBP (NASDAQ)
| 25 M Common Shares Outstanding (140.1M Fully Diluted) — —— - SYD] Ssnbameessofaaize FINANCIAL PROFILE: CRBP (NASDAQ)
Slide 41: A Team With a Proven Record of Execution
A Team With a Proven Record of Execution Yuval Cohen, PhD Chief Executive Officer, Director Executive leadership experience in inflammatory disease drug Barbara White, MD Chief Medical Officer and Head of Research Previous academician with industry, clinical development, and medical affairs experien
Slide 42: An Experienced and Engaged Board of Directors
An Experienced and Engaged Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, 0.6. including Special Envoy to China; Former CEO of PhRMA Rachelle Jacques Director More than 25-year professional career, experience in US. and global bi
Slide 43: Connecting Innovation to Purpose
Connecting Innovation to Purpose NASDAQ: CRBP + CorbusPharma.com - @CorbusPharma
Slide 44: RESOLVE-1 Phase 3 in Systemic Sclerosis
RESOLVE-1 Phase 3 in Systemic Sclerosis Largest ever study in diffuse cutaneous systemic PRIMARY EFFICACY ENDPOINT: MEDIAN ACR CRISS SCORES AT WEEK 52 sclerosis (n=365, 52-weeks, 76 global sites) Visit 11 Lenabasum 20 mg sr ' ‘ . (Week 52) BID- N= 120 First in a group of studies to allow patients to
Slide 45: Subjects Treated With Lenabasum Added to Established IST
PHASE 3 - Subjects Treated With Lenabasum 20 mg BID Added to Established IST (> 2 Year Duration) Had Stable FVC % Predicted Nominal P = 0.039 . a4 Week 52, 2-sample t -test <s 2 aa faa ra. l POST-HOC ANALYSES BB. 12 S54 Subjects treated with lenabasum < £ 20 mg BID added to established 2 6 immunosup
Slide 46: CRB-4001 Acts In a Variety of Key Metabolic Pathways
CRB-4001 Acts Ina Variety of Key Metabolic Pathways ¥ Hyperglycemia+ Hyperglycemia CB,R antagonism/absence R eR R Apical Basal Apical Basal membrane membrane membrane membrane inden. et at Modulation of RenalGLUI2y the Cannabinois1Recepter Implications for the Treatment of Diabetic Nephropathy. Jour
Corbus Pharmaceuticals Holdings — Investor Presentation (June 2021) on 6ix